^
    CANCER:

    Kidney Medullary Carcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    PD1 inhibitor
    		0
    PD1 inhibitor
    nivolumab
    pembrolizumab
    cabozantinib tablet
    		1
    Multi-tyrosine kinase inhibitor
    pazopanib
    midostaurin
    2
    mTOR inhibitor
    everolimus
    temsirolimus
    3
    VEGFR inhibitor, PD1 inhibitor
    pembrolizumab + axitinib
    4
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    5
    VEGFR inhibitor
    VEGFR inhibitor
    axitinib
    6
    IFNα stimulant, VEGF-A inhibitor
    bevacizumab + pegylated interferon α -2a
    7
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    8
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    9
    VEGF-A inhibitor
    bevacizumab
    10
    AXL inhibitor, GAS6 inhibitor
    AVB-500
    11
    PD1 inhibitor, Multi-tyrosine kinase inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab + cabozantinib tablet
    12
    HDAC inhibitor
    vorinostat
    13
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    14
    Tubulin inhibitor
    vinblastine
    15
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    16
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    17
    HIF-2α antagonist
    MK-3795
    18
    HIF-2α inhibitor
    belzutifan
    19
    Immunotherapy
    Immunotherapy
    20
    Immunotherapy, Tyrosine kinase inhibitor
    Immunotherapy + Tyrosine kinase inhibitor
    21
    VEGFR inhibitor, Immunotherapy
    Immunotherapy + VEGFR inhibitor
    22
    PD-L1 inhibitor
    PD-L1 inhibitor
    23
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    24
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    25
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    26
    VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
    tivozanib
    27
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    28
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor, FLT3 inhibitor
    ABT-869
    29
    AXL inhibitor, Multi-tyrosine kinase inhibitor, GAS6 inhibitor
    cabozantinib tablet + AVB-500
    30
    ATR inhibitor
    M6620
    31
    RAC1 inhibitor
    NSC23766
    32
    PARP inhibitor
    talazoparib
    33
    FGFR4 inhibitor
    BLU 9931
    34
    DNA synthesis inhibitor
    cisplatin
    No biomarker
    RNASET2 overexpression
    PBRM1 mutation
    PD-L1 expression
    PD-L1 overexpression
    PBRM1 deletion
    VHL mutation
    VHL deletion
    VHL promoter methylation
    BAP1 mutation
    ERVE-4 expression
    SYNE1 mutation
    HMOX1 expression
    CDKN2A mutation
    KDR C482R
    CTLA4 promoter hypomethylation
    NANOGNB mutation
    TNFRSF9 elevation
    PD-L1 expression + CD14 positive
    LAG3 positive + CD4 positive
    TNFRSF9 positive + CD8 positive
    TNFRSF9 positive + CD4 positive
    FOLH1 overexpression
    ISLR overexpression
    AXL elevation + GAS6 elevation
    TLR3 overexpression
    WDR72 overexpression + PBRM1 mutation
    WDR72 overexpression
    ARID2 H1495fs*8
    SMARCB1 deletion
    MTOR Q2223K
    MET fusion
    NF2 mutation
    Immune response prediction signature
    DDR
    SETD2 deletion
    CD276 expression
    TP53 mutation
    AXL overexpression + PD-L1 expression
    TERC overexpression
    DKC1 overexpression
    AXL overexpression
    DDX39B overexpression
    MCAM overexpression
    HIF1A expression
    DAPK1 underexpression
    IL6 elevation
    EPAS1 overexpression
    VEGFA elevation
    CXCL8 elevation
    IL7 elevation
    PTTG1 overexpression
    CXCR4 overexpression
    SETD2 mutation
    FGFR4 amplification
    EPAS1 G323E
    TNFSF13B elevation
    CXCL13 elevation
    SPI1 overexpression
    CD27 overexpression
    EPAS1 S304M